Sulbactam sodium |
| Catalog No.GC12665 |
Sulbactam sodium, a β-lactamase inhibitor, is commonly used in combination with β-lactam antibiotics to enhance their efficacy against drug-resistant bacteria.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 69388-84-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sulbactam sodium, a β-lactamase inhibitor, is commonly used in combination with β-lactam antibiotics to enhance their efficacy against drug-resistant bacteria[1]. One of the reasons for the development of bacterial resistance to β-lactam antibiotics is the production of β-lactamases[2]. Sulbactam sodium irreversibly binds to bacterial β-lactamases, preventing these enzymes from hydrolyzing β-lactam antibiotics[3], thereby preserving the ability of β-lactam antibiotics to inhibit bacterial cell wall formation[4].
In vitro, when Sulbactam sodium (0.5, 1, 2, 4, 8mg/L) is combined with β-lactam antibiotics (ampicillin, cefoperazone, imipenem) at various ratios (2:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3) to treat Acinetobacter baumannii, Sulbactam sodium significantly enhances the bactericidal activity of the antibiotics against A. baumannii [5]. Zidebactam (4mg/L) combined with Sulbactam sodium (0.12–512mg/L) significantly restores the susceptibility of carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates to Sulbactam sodium. Among 43 CRAB strains, 84% showed a ≥2-fold decrease in MIC of Sulbactam sodium when tested in combination with Zidebactam [6].
In vivo, Sulbactam sodium (10.0mg/kg) was administered via intracerebroventricular injection to prevent ischemic injury in a rat model of cerebral ischemia. The administration began 5 days before the occurrence of ischemia, once daily for a total of 5 consecutive days. Sulbactam sodium pretreatment significantly improved the binding characteristics of glutamate transporter-1 (GLT-1) and inhibited the increase in extracellular glutamate concentration in the CA1 region of the hippocampus in ischemic rats. Sulbactam sodium also protected neurons in the CA1 region and alleviated ischemia-induced delayed neuronal death[7]. Sulbactam sodium (400, 1000, and 2000mg/kg/d) was administered via intraperitoneal injection to induce epilepsy in a chronic renal failure (CRF) mouse model, starting immediately after the CRF model was established. Sulbactam sodium at all three doses significantly induced epileptic seizures in a dose-dependent manner in CRF mice, leading to death. In particular, the high dose (2000mg/kg/d) of Sulbactam sodium caused seizures in CRF mice as early as 3 days after administration[8].
References:
[1] Noguchi JK, Gill MA. Sulbactam sodium: a beta-lactamase inhibitor. Clin Pharm. 1988 Jan;7(1):37-51.
[2] Tooke CL, Hinchliffe P, Bragginton EC, et al. β-Lactamases and β-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019 Aug 23;431(18):3472-3500.
[3] Akova M. Sulbactam sodium-containing beta-lactamase inhibitor combinations. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:185-8.
[4] Fu Y, Asempa TE, Kuti JL. Unraveling Sulbactam sodium-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii. Expert Rev Anti Infect Ther. 2025 Jan;23(1):67-78.
[5] Wang L, Chen Y, Han R, et al. Sulbactam sodium Enhances in vitro Activity of β-Lactam Antibiotics Against Acinetobacter baumannii. Infect Drug Resist. 2021 Sep 28;14:3971-3977.
[6] Cedano J, Baez M, Pasteran F, et al. Zidebactam restores Sulbactam sodium susceptibility against carbapenem-resistant Acinetobacter baumannii isolates. Front Cell Infect Microbiol. 2022 Jul 8;12:918868.
[7] Gu WW, Cui X, Liu LZ, et al. Sulbactam sodium improves binding property and uptake capacity of glutamate transporter-1 and decreases glutamate concentration in the CA1 region of hippocampus of global brain ischemic rats. Amino Acids. 2021 Nov;53(11):1649-1661.
[8] Wu Y, Gu D, Li J, et al. Role of the gut microbiota in cefoperazone/Sulbactam sodium-induced epilepsy in mice with chronic renal failure. Ren Fail. 2024 Dec;46(2):2371551.
| Cell experiment [1]: | |
Cell lines | Clinical isolates of carbapenem-resistant Acinetobacter baumannii (CRAB) |
Preparation Method | A total of 43 geographically and genetically distinct CRAB clinical strains containing different mechanisms of resistance (OXA-23, OXA-58, IMP-1, NDM-1, ISAba1-OXA-66) were used to test Sulbactam sodium or Sulbactam sodium in combination with zidebactam. Additionally, three reference strains (AB0057, AB5075, and AYE) were included. The strains were tested against Sulbactam sodium (range 0.12–512mg/l) and Sulbactam sodium plus 4mg/l zidebactam using the microdilution method according to CLSI Standards. |
Reaction Conditions | Sulbactam sodium (range 0.12–512mg/l) and Sulbactam sodium plus 4mg/l zidebactam |
Applications | Sulbactam sodium in combination with zidebactam significantly restored Sulbactam sodium susceptibility against CRAB strains. The combination showed a ≥2 dilutions decrease in Sulbactam sodium MICs in 84% of the isolates tested. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats |
Preparation Method | Global brain ischemia was induced by tightening nylon sutures to block the blood flow of the bilateral common carotid arteries for 8 minutes. The rats were treated with Sulbactam sodium (10.0mg/kg) via lateral ventricle injection once daily for five consecutive days prior to ischemia. After the last administration, global brain ischemia or sham treatment was performed. The sham rats received the same treatments except the bilateral vertebral artery and bilateral common carotid artery were not occluded. The rats were sacrificed at various time points after reperfusion for different assays. |
Dosage form | 10.0mg/kg; i.c.v. |
Applications | Sulbactam sodium pretreatment significantly improved the binding characteristics of glutamate transporter-1 (GLT-1) and inhibited the increase in extracellular glutamate concentration in the CA1 region of the hippocampus in ischemic rats. Sulbactam sodium also protected neurons in the CA1 region and alleviated ischemia-induced delayed neuronal death. |
References: | |
| Cas No. | 69388-84-7 | SDF | |
| Chemical Name | sodium;(2S,5R)-3,3-dimethyl-4,4,7-trioxo-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | ||
| Canonical SMILES | CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)[O-])C.[Na+] | ||
| Formula | C8H10NO5S.Na | M.Wt | 255.22 |
| Solubility | ≥ 10.75mg/mL in Water | Storage | Store at -20°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9182 mL | 19.5909 mL | 39.1819 mL |
| 5 mM | 783.6 μL | 3.9182 mL | 7.8364 mL |
| 10 mM | 391.8 μL | 1.9591 mL | 3.9182 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *